Guardant Health, Inc. Common Stock

The FDA approved Guardant Health's Guardant360 CDx blood test as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Pfizer's Braftovi treatment combined with cetuximab and chemotherapy. This marks the 25th companion diagnostic indication for the platform and expands non-invasive ge...

The pan-genomic and multi-gene panel testing market is projected to grow from US$ 8.9 billion in 2024 to US$ 25.9 billion by 2032, driven by a 12.04% CAGR. Growth is fueled by rising clinical adoption of genomics-driven diagnostics, FDA approvals of comprehensive genomic profiling tests, advances in NGS technology and bioinformatics, and expandin...

Eventide Asset Management sold 114,922 shares of Mirum Pharmaceuticals in Q3, but the position's value increased by approximately $50.70 million to $184.92 million due to the stock's 89% surge over the past year. The share reduction appears to be portfolio management rather than a loss of confidence, as Mirum posted strong Q3 revenue growth of 47...

The Pre-Dx oncology market is entering a high-growth phase, driven by breakthrough non-invasive cancer detection technologies like liquid biopsy and multi-cancer early detection tests. The market is expected to generate substantial revenue growth, with North America leading and Asia Pacific showing the fastest growth potential.

The global oncology biomarker market is projected to grow from USD 34.16 billion in 2024 to USD 113.54 billion by 2034, with a 12.73% CAGR, driven by precision medicine, technological advances, and increasing cancer incidence.